Pharmacoeconomic aspects related to the 13-valent pneumococcal conjugate vaccine: preliminary analysis of the data from the ASL of Viterbo
DOI:
https://doi.org/10.7175/fe.v15i4.980Keywords:
Streptococcus pneumoniae, Vaccinal Prevention, Economic impactAbstract
INTRODUCTION: Streptococcus pneumoniae is a pathogen of considerable importance to public health because it causes morbidity and mortality on the world population. It has more than 90 serotypes with different epidemiological characteristics and pathogenicity. Some categories of the population are particularly vulnerable to infection. The Regional Plan for the Prevention of Lazio for vaccination, based on the national plan for the prevention for vaccination involves the active offer of vaccination no 13-valent PCV, with a target of at least 90% in children 24 months of age.
OBJECTIVE: To begin to assess the real economic impact of disease attributable to Pneumococcus, starting from the analysis of hospital discharge records (SDO) of the Viterbo's ASL.
METHODS: The model is structured follows the observational approach of 33 months, from January 2012 to September 2014, selecting the SDO with a principal diagnosis of Streptococcus Pneumoniae diseases and those with a principal diagnosis of respiratory diseases without etiological diagnosis, which, with good approximation, it can be considered responsible for Streptococcus pneumoniae 40%.
RESULTS: From the preliminary analysis of the data, evaluating only patients diagnosed due to Pneumococcus, is known as the only pediatric cases hospitalized are between 0 and 1 year. Therefore one might assume that vaccination disbursed to the child population with 13-valent PCV, has ensured effective protection to persons of the age group 2-18 years.
CONCLUSIONS: The importance of this study is the observation conducted on an ASL, (similar in size and catchment area to many Italian realty) of the vaccination coverage effects, as provided by PRPV Lazio Region, on hospitalizations by Pneumococcus. The study offers a moment of reflection for decision makers, as it would be interesting to conduct pharmacoeconomic’s analysis in the presence of vaccination strategies extended to adults, especially for those at risk, associated with diagnostic tests etiological more specific.
References
World Health Organization (WHO). The World health report 2004: changing history. Disponibile su: http://www.who.int/whr/2004/en/report04_en.pdf (ultimo accesso novembre 2014)
Rudan I, Boschi-Pinto C, Biloglav Z et al. Epidemiology and etiology of childhoodpneumonia. Bull World Health Organ 2008; 86: 408-16; http://dx.doi.org/10.2471/BLT.07.048769
Ministero della salute. Rapporto annuale sull’attività di ricovero ospedaliero. Dati SDO 2009. Disponibile su: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1491_allegato.pdf (ultimo accesso novembre 2014)
Ministero della salute. Rapporto annuale sull’attività di ricovero ospedaliero. Dati SDO 2010 Disponibile su: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1690_allegato.pdf (ultimo accesso novembre 2014)
Moriondo M, Nieddu F, Pecile P, et al. Le infezioni pneumococciche dell’adulto in Italia e la possibilità di prevenzione.quale ruolo per i nuovi vaccini coniugati? Rivista Società Italiana di Medicina Generale 2012; 2: 62-5
Gertz RE Jr, Li Z, Pimenta FC, et al.; Active Bacterial Core Surveillance Team. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010; 201: 770-5; http://dx.doi.org/10.1086/650496
Pneumovax® – Riassunto delle Caratteristiche di Prodotto
No author listed. Efficacia e benefici del vaccino pneumococcico coniugato: una review della letteratura. Speciale Vaccinare Oggi 2007
Prevenar 13 – Riassunto delle Caratteristiche di Prodotto
Ministero della Salute. Piano Nazionale Prevenzione Vaccinale 2012/2014. Disponibile su: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf (ultimo accesso novembre 2014)
Decreto del Commissario ad acta n.U00192 del 5/11/2012. “Presa d’atto dell’Intesa ai sensi dell’art. 8 comma 6 della Legge 5 giugno 2003 n. 131 tra il Governo, le Regioni e le Province autonome di Trento e Bolzano sul documento recante Piano Nazionale Prevenzione Vaccinale 2012 – 2014”. Piano Regionale Prevenzione Vaccinale 2012-2014, Regione Lazio
DRL B7030/2011, Gara Regionale Centralizzata relativa alla fornitura di vaccini per uso umano. Regione Lazio
Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012; 67: 540-5; http://dx.doi.org/10.1136/thoraxjnl-2011-201092
Melissa C. Overman, DO, MPH Time for Changes in Pneumococcal Vaccination of Adults? J Am Osteopath Assoc 2011; 111(10 Suppl 6): S19-22
Geo demo ISTAT. Demografia in cifre. Disponibile su: http://demo.istat.it/index.html (ultimo accesso novembre 2014)
DGR 877/05. Piano Regionale Vaccini, Regione Lazio e DGR 133/08. Aggiornamento piano regionale vaccini. Regione Lazio
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
